Literature DB >> 22144485

Live attenuated Salmonella vaccines displaying regulated delayed lysis and delayed antigen synthesis to confer protection against Mycobacterium tuberculosis.

María Dolores Juárez-Rodríguez1, Jiseon Yang, Rebin Kader, Praveen Alamuri, Roy Curtiss, Josephine E Clark-Curtiss.   

Abstract

Live recombinant attenuated Salmonella vaccine (RASV) strains have great potential to induce protective immunity against Mycobacterium tuberculosis by delivering M. tuberculosis antigens. Recently, we reported that, in orally immunized mice, RASV strains delivering the M. tuberculosis early secreted antigenic target 6-kDa (ESAT-6) protein and culture filtrate protein 10 (CFP-10) antigens via the Salmonella type III secretion system (SopE amino-terminal region residues 1 to 80 with two copies of ESAT-6 and one copy of CFP-10 [SopE(Nt80)-E2C]) afforded protection against aerosol challenge with M. tuberculosis. Here, we constructed and evaluated an improved Salmonella vaccine against M. tuberculosis. We constructed translational fusions for the synthesis of two copies of ESAT-6 plus CFP-10 fused to the OmpC signal sequence (OmpC(SS)-E2C) and amino acids 44 to 338 of antigen 85A (Ag85A(294)) flanked by the signal sequence (SS) and C-terminal peptide (CT) of β-lactamase (Bla(SS)-Ag85A(294)-Bla(CT)) to enable delivery via the Salmonella type II secretion system. The genes expressing these proteins were cloned as an operon transcribed from P(trc) into isogenic Asd(+)/MurA(+) pYA3681 lysis vector derivatives with different replication origins (pBR, p15A, pSC101), resulting in pYA4890, pYA4891, and pYA4892 for SopE(Nt80)-E2C/Ag85A(294) synthesis and pYA4893 and pYA4894 for OmpC(SS)-E2C/Ag85A(294) synthesis. Mice orally immunized with the RASV χ11021 strain engineered to display regulated delayed lysis and regulated delayed antigen synthesis in vivo and harboring pYA4891, pYA4893, or pYA4894 elicited significantly greater humoral and cellular immune responses, and the RASV χ11021 strain afforded a greater degree of protection against M. tuberculosis aerosol challenge in mice than RASVs harboring any other Asd(+)/MurA(+) lysis plasmid and immunization with M. bovis BCG, demonstrating that RASV strains displaying regulated delayed lysis with delayed antigen synthesis resulted in highly immunogenic delivery vectors for oral vaccination against M. tuberculosis infection.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22144485      PMCID: PMC3264310          DOI: 10.1128/IAI.05526-11

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  65 in total

1.  Recombinant bacillus calmette-guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model.

Authors:  M A Horwitz; G Harth; B J Dillon; S Maslesa-Galic'
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-05       Impact factor: 11.205

2.  ESAT-6 subunit vaccination against Mycobacterium tuberculosis.

Authors:  L Brandt; M Elhay; I Rosenkrands; E B Lindblad; P Andersen
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

Review 3.  Pulmonary defences to acute respiratory infection.

Authors:  Rosemary J Boyton; Peter J Openshaw
Journal:  Br Med Bull       Date:  2002       Impact factor: 4.291

4.  Protective efficacy against tuberculosis of ESAT-6 secreted by a live Salmonella typhimurium vaccine carrier strain and expressed by naked DNA.

Authors:  H J Mollenkopf; D Groine-Triebkorn; P Andersen; J Hess; S H Kaufmann
Journal:  Vaccine       Date:  2001-07-16       Impact factor: 3.641

5.  Regulated antigen expression in live recombinant Salmonella enterica serovar Typhimurium strongly affects colonization capabilities and specific CD4(+)-T-cell responses.

Authors:  D Bumann
Journal:  Infect Immun       Date:  2001-12       Impact factor: 3.441

6.  Immune responses to recombinant pneumococcal PspA antigen delivered by live attenuated Salmonella enterica serovar typhimurium vaccine.

Authors:  Ho Young Kang; Jay Srinivasan; Roy Curtiss
Journal:  Infect Immun       Date:  2002-04       Impact factor: 3.441

7.  Immune responses dependent on antigen location in recombinant attenuated Salmonella typhimurium vaccines following oral immunization.

Authors:  Ho Young Kang; Roy Curtiss
Journal:  FEMS Immunol Med Microbiol       Date:  2003-07-15

Review 8.  The protective role of antibody responses during Mycobacterium tuberculosis infection.

Authors:  F Abebe; G Bjune
Journal:  Clin Exp Immunol       Date:  2009-08       Impact factor: 4.330

9.  Mapping of murine Th1 helper T-Cell epitopes of mycolyl transferases Ag85A, Ag85B, and Ag85C from Mycobacterium tuberculosis.

Authors:  S D'Souza; V Rosseels; M Romano; A Tanghe; O Denis; F Jurion; N Castiglione; A Vanonckelen; K Palfliet; Kris Huygen
Journal:  Infect Immun       Date:  2003-01       Impact factor: 3.441

10.  Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis.

Authors:  Alexander S Pym; Priscille Brodin; Laleh Majlessi; Roland Brosch; Caroline Demangel; Ann Williams; Karen E Griffiths; Gilles Marchal; Claude Leclerc; Stewart T Cole
Journal:  Nat Med       Date:  2003-04-14       Impact factor: 53.440

View more
  13 in total

1.  Listeria-Vectored Vaccine Expressing the Mycobacterium tuberculosis 30-Kilodalton Major Secretory Protein via the Constitutively Active prfA* Regulon Boosts Mycobacterium bovis BCG Efficacy against Tuberculosis.

Authors:  Qingmei Jia; Barbara Jane Dillon; Saša Masleša-Galić; Marcus A Horwitz
Journal:  Infect Immun       Date:  2017-08-18       Impact factor: 3.441

Review 2.  Bacterial type III secretion system as a protein delivery tool for a broad range of biomedical applications.

Authors:  Fang Bai; Zhenpeng Li; Akihiro Umezawa; Naohiro Terada; Shouguang Jin
Journal:  Biotechnol Adv       Date:  2018-02-02       Impact factor: 14.227

3.  Immunogenic Properties of Lactobacillus plantarum Producing Surface-Displayed Mycobacterium tuberculosis Antigens.

Authors:  Katarzyna Kuczkowska; Charlotte R Kleiveland; Rajna Minic; Lars F Moen; Lise Øverland; Rannei Tjåland; Harald Carlsen; Tor Lea; Geir Mathiesen; Vincent G H Eijsink
Journal:  Appl Environ Microbiol       Date:  2016-12-30       Impact factor: 4.792

4.  A colanic acid operon deletion mutation enhances induction of early antibody responses by live attenuated Salmonella vaccine strains.

Authors:  Shifeng Wang; Huoying Shi; Yuhua Li; Zhaoxing Shi; Xin Zhang; Chang-Ho Baek; Tabor Mothershead; Roy Curtiss
Journal:  Infect Immun       Date:  2013-06-17       Impact factor: 3.441

5.  Novel vaccine antigen combinations elicit protective immune responses against Escherichia coli sepsis.

Authors:  Melha Mellata; Natalie M Mitchell; Florian Schödel; Roy Curtiss; Gerald B Pier
Journal:  Vaccine       Date:  2015-12-18       Impact factor: 3.641

Review 6.  Vaccines: from empirical development to rational design.

Authors:  Christine Rueckert; Carlos A Guzmán
Journal:  PLoS Pathog       Date:  2012-11-08       Impact factor: 6.823

Review 7.  Bacteria in Cancer Therapy: Renaissance of an Old Concept.

Authors:  Sebastian Felgner; Dino Kocijancic; Michael Frahm; Siegfried Weiss
Journal:  Int J Microbiol       Date:  2016-03-08

Review 8.  Live bacterial vaccine vectors: an overview.

Authors:  Adilson José da Silva; Teresa Cristina Zangirolami; Maria Teresa Marques Novo-Mansur; Roberto de Campos Giordano; Elizabeth Angélica Leme Martins
Journal:  Braz J Microbiol       Date:  2015-03-04       Impact factor: 2.476

9.  aroA-Deficient Salmonella enterica Serovar Typhimurium Is More Than a Metabolically Attenuated Mutant.

Authors:  Sebastian Felgner; Michael Frahm; Dino Kocijancic; Manfred Rohde; Denitsa Eckweiler; Agata Bielecka; Emilio Bueno; Felipe Cava; Wolf-Rainer Abraham; Roy Curtiss; Susanne Häussler; Marc Erhardt; Siegfried Weiss
Journal:  MBio       Date:  2016-09-06       Impact factor: 7.867

10.  Live attenuated Salmonella typhimurium vaccines delivering SaEsxA and SaEsxB via type III secretion system confer protection against Staphylococcus aureus infection.

Authors:  Chen Xu; Bao-Zhong Zhang; Qiubin Lin; Jian Deng; Bin Yu; Smriti Arya; Kwok-Yung Yuen; Jian-Dong Huang
Journal:  BMC Infect Dis       Date:  2018-04-25       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.